Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1989636 | 0.88 | SMN1; SMN2 (0.42) | KMT2AMEN1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL1551573 | 0.87 | SMN1; SMN2 (0.43) | KMT2AMEN1ALDH1A1L3MBTL1F2 | |
| SCHEMBL1550616 | 0.86 | FFAR2 (0.37) | KMT2AMEN1ALDH1A1TSHRF2 | |
| SCHEMBL1551036 | 0.85 | CNR1 (0.38) | — | |
| SCHEMBL1989938 | 0.85 | RHOC (0.41) | KMT2AMEN1ALDH1A1KDM4EF2 | |
| SCHEMBL1551280 | 0.85 | LMNA (0.46) | KMT2AALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL1990733 | 0.84 | F2 (0.38) | KMT2AMEN1F2SMN1; SMN2 | |
| SCHEMBL3401787 | 0.84 | F2 (0.39) | KMT2AMEN1F2SMN1; SMN2 | |
| SCHEMBL976717 | 0.84 | F2 (0.39) | KMT2AMEN1F2SMN1; SMN2 | |
| SCHEMBL1990364 | 0.83 | F2 (0.38) | KMT2AF2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | claimed |
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | C1R, TACR1, C1S | KMT2A 2630/4885MEN1 1088/4885ALDH1A1 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.